Home Business The FDA declined to approve one of biotech’s most closely watched cancer drugs
Business

The FDA declined to approve one of biotech’s most closely watched cancer drugs

Share
The FDA declined to approve one of biotech’s most closely watched cancer drugs
Share


The regulator told Summit Therapeutics that the lung-cancer drug needs to prove it can help people live longer.

Source link

Share

Leave a comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Keep in touch

Subscribe to our newsletter to get our newest articles instantly!

    Copyright 2025. All rights reserved